Immune recovery after autologous or rhG-CSF primed PBSC transplantation

Phenotypic changes in neutrophils after rhG-CSF administration in non-Hodgkin's lymphoma patients undergoing PBSC transplantation or conventional chemotherapy.

a preleukapheresis PB CD34+ cell concentration ≥ 40/μL was significantly related to the collection of at least 23106 CD34+ cells/kg in a single apheresis, as previously reported.9,10 In addition to the above data, we found that to obtain a target number of 23106 CD34+ cells/kg, PB CD34+ cell concentrations ≤ 30/μL are associated with the need for at least two leukapheresis procedures and PB con...

GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.

BACKGROUND G-CSF and GM-CSF have both been shown to decrease the time to hematopoietic recovery when administered after autologous BM or peripheral stem cell re-infusion. However, few studies have compared G-CSF and GM-CSF to determine which is the preferred myeloid growth factor. METHODS This study compares a prospectively accrued cohort of 22 patients receiving GM-CSF with a historical coho...

Severe autoimmune hyperthyroidism after donation of rhG-CSF-primed allogeneic peripheral blood progenitor cells

Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors.

T-cell and B-cell reconstitution was studied in nine patients who received fluorescence activated cell sorter (FACS)-sorted autologous CD34+ hematopoietic progenitor cells (HPC). The mean numbers of T cells (CD3+), B cells (CD19+) and CD34+ HPC administered to each patient were .004, .002, and 1.8 x 10(6) cells/kg, respectively. After high-dose myeloablative chemotherapy (busulfan, cyclophospha...

Immune reconstitution after autologous hematopoietic stem cell transplantation.

Autologous hematopoietic stem cell transplantation has proved to be an effective treatment for certain hematologic malignancies. However, relapse rates are high during the first year after transplantation. These relapses are attributed to the failure of high-dose chemotherapy to eradicate minimal residual malignant disease. In allogeneic hematopoietic stem cell transplantation, the higher antit...